V
ACAD icon

Veritable’s Acadia Pharmaceuticals ACAD Stock Holding History

Veritable’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,157
Closed -$228K – 736
2016
Q3 		$228K Buy
7,157
+379
+6% +$12.8K 0.01% 654
2016
Q2 		$220K Buy
+6,778
New +$227K 0.01% 647

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Veritable's ACAD Position: Q4 2016 in Review

Veritable sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 7,157 shares — an estimated $228K sold.

Veritable first reported a position in ACAD in Q2 2016 and held it in 2 quarters. The position peaked at $228K in Q3 2016. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Veritable reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Veritable sold 7,157 Acadia Pharmaceuticals shares in Q4 2016, an estimated $228K.
  • Veritable first reported a position in Acadia Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Veritable's Acadia Pharmaceuticals position peaked at $228K in Q3 2016.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Veritable's 13F filing for Q4 2016, filed 14 Feb 2017.